Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.65 |
| ▸ | CASP6 | P55212 | 2/20 | 0.65 |
| ▸ | RAD52 | P43351 | 1/20 | 0.59 |
| ▸ | CASP7 | P55210 | 1/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.54 |
| ▸ | HSP90AB1 | P08238 | 11/20 | 0.54 |
| ▸ | HTR1A | P08908 | 3/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14424700 | 1.00 | NSD2 (0.65) | NSD2CASP6RAD52CASP7HSP90AA1 | |
| Sitamaquine SCHEMBL29811198 | 1.00 | NSD2 (0.65) | NSD2CASP6RAD52CASP7HSP90AA1 | |
| Sitamaquine SCHEMBL1230457 | 0.99 | NSD2 (0.64) | NSD2CASP6RAD52CASP7HSP90AA1 | |
| Sitamaquine SCHEMBL1267745 | 0.99 | NSD2 (0.64) | NSD2CASP6RAD52CASP7HSP90AA1 | |
| Sitamaquine SCHEMBL1650398 | 0.99 | NSD2 (0.64) | NSD2CASP6RAD52CASP7HSP90AA1 | |
| SCHEMBL14424702 | 0.93 | NSD2 (0.59) | NSD2CASP6RAD52CASP7HSP90AA1 | |
| SCHEMBL14424685 | 0.93 | NSD2 (0.64) | NSD2CASP6RAD52CASP7HSP90AA1 | |
| SCHEMBL14424692 | 0.93 | NSD2 (0.64) | NSD2CASP6RAD52CASP7HSP90AA1 | |
| Sitamaquine SCHEMBL2933465 | 0.89 | NSD2 (0.54) | NSD2CASP6RAD52CASP7HSP90AA1 | |
| SCHEMBL10731681 | 0.85 | NSD2 (0.71) | NSD2CASP6RAD52CASP7HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-3701954-A2 | USE OF AVERMECTIN DERIVATIVE FOR INCREASING BIOAVAILABILITY AND EFFICACY OF MACROCYLIC LACTONES | Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (FR) | 2020-09-02 | — | — | EP | claimed |
| EP-2768513-B1 | USE OF AVERMECTIN DERIVATIVE FOR INCREASING BIOAVAILABILITY AND EFFICACY OF MACROCYLIC LACTONES | INST NAT DE LA RECH AGRONOMIQUE INRA (FR) | 2019-12-25 | — | — | EP | claimed |
| US-20150306035-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CONVENTIONAL LIPOSOMES AND PROLONGED-CIRCULATION LIPOSOMES FOR THE TREATMENT OF VISCERAL LEISHMANIASIS | FUNDACÃO DE AMPARO A PESQUISA DO ESTADO DE MINAS GERAIS - FAPEMIG (BR) | 2015-10-29 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20140256619-A1 | USE OF AVERMECTIN DERIVATIVE FOR INCREASING BIOAVAILABILITY AND EFFICACY OF MACROCYLIC LACTONES | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (FR) | 2014-09-11 | — | — | US | claimed |
| EP-2768513-A2 | USE OF AVERMECTIN DERIVATIVE FOR INCREASING BIOAVAILABILITY AND EFFICACY OF MACROCYLIC LACTONES | Institut National De La Recherche Agronomique (INRA) (FR) | 2014-08-27 | — | — | EP | claimed |
| EP-2655314-A1 | MULTI- API LOADING PRODRUGS | Alkermes Pharma Ireland Limited (IE) | 2013-10-30 | — | — | EP | claimed |
| EP-1962862-B1 | ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEROF | AETERNA ZENTARIS GMBH (DE) | 2013-09-04 | — | — | EP | claimed |
| WO-2013057208-A1 | COMPOSITIONS AND METHODS FOR REDUCING THE PROLIFERATION AND VIABILITY OF MICROBIAL AGENTS | TARGETED DELIVERY TECHNOLOGIES LIMITED (MT) | 2013-04-25 | — | — | WO | claimed |
| CN-101340918-A | Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof | AETERNA ZENTARIS GMBH (DE) | 2009-01-07 | — | — | CN | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1962862-A2 | ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEROF | AEterna Zentaris GmbH (DE) | 2008-09-03 | — | — | EP | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2008022422-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TRIPANOSSOMIASIS AND CHAGAS DISEASE | FUNDAÇÃO UNIVERSIDADE DE BRASÍLIA (BR) | 2008-02-28 | — | — | WO | claimed |
| US-20070167408-A1 | NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF | ZENTARIS GMBH (DE) | 2007-07-19 | — | — | US | claimed |
| WO-2007071658-A2 | ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF | ÆTERNA ZENTARIS GMBH (DE) | 2007-06-28 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-4302459-A | Liposome carriers in leishmaniasis chemotherapy with 8-aminoquinoline derivatives | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1981-11-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256619-A1 | USE OF AVERMECTIN DERIVATIVE FOR INCREASING BIOAVAILABILITY AND EFFICACY OF MACROCYLIC LACTONES | P4HTM, UNC93B1, MTCH2 | NSD2 3946/4885CASP6 1233/4885RAD52 3652/4885 |
| US-20070167408-A1 | NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF | PHOSPHO1, PTDSS1, PTDSS2 | NSD2 3453/4885CASP6 401/4885RAD52 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.